- 50% of all biotechs are down 50% this year - Share price is not an indicator of how well the company is doing - Current market is horrific for biotechs
We have the first successful nGBM trial in a decade+. The first successful rGBM trial in nearly 3 decades.
Is this you playing that double secret agent trying to goad more shorts into a trap so you can bask in your $15 per share end of year target price?!
Let me help, what you're missing is all the time wasted on this forum spewing noise about the share price and the stock being junk, and dumps and NOISE.